Publications

Desjardins, A., D. A. Reardon, J. A. Quinn, J. N. Rich, J. J. Vredenburgh, S. Sathornsumetee, A. Salvado, and H. S. Friedman. “Phase II trial of imatinib mesylate and hydroxyurea for grade III malignant gliomas..” In Journal of Clinical Oncology, 24:76S-76S. AMER SOC CLINICAL ONCOLOGY, 2006.

Scholars@Duke

Harpole, D. H., R. Petersen, S. Mukherjee, A. Bild, H. Dressman, R. Kratzke, M. J. Kelley, et al. “A genomic strategy to refine prognosis in early stage non-small cell lung carcinoma (NSCLC)..” J Clin Oncol 24, no. 18_suppl (June 20, 2006).

PMID
27953212
Scholars@Duke

Rich, J. N., Q. Shi, A. B. Hjelmeland, S. T. Keir, S. Wickman, G. Wu, D. Jackson, O. Ohmori, D. D. Bigner, and H. S. Friedman. “A novel low molecular weight inhibitor of focal adhesion kinase and insulin-like growth factor-1 receptor, TAE226, inhibits glioma growth..” J Clin Oncol 24, no. 18_suppl (June 20, 2006).

PMID
27954359
Scholars@Duke

Vredenburgh, J. J., C. Bohlin, D. A. Reardon, A. Desjardins, J. Quinn, J. Rich, S. Sathornsumetee, L. B. Marks, A. H. Friedman, and H. S. Friedman. “Tinzaparin prophylaxis against thromboembolic complications in brain tumor patients..” J Clin Oncol 24, no. 18_suppl (June 20, 2006).

PMID
27952290
Scholars@Duke

Chang, Wei, Jun Chen, Qing-yi Wei, and Xue-min Chen. “Effects of Brn-3a protein and RNA expression in rat brain following low-level lead exposure during development on spatial learning and memory..” Toxicol Lett 164, no. 1 (June 20, 2006): 63–70. https://doi.org/10.1016/j.toxlet.2005.11.011.

PMID
16384672
Full Text

Gajewski, T. F., D. Niedzwiecki, J. Johnson, G. Linette, C. Bucher, M. Blaskovich, S. Sebti, and F. Haluska. “Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104..” In Journal of Clinical Oncology, 24:456S-456S. AMER SOC CLINICAL ONCOLOGY, 2006.

Scholars@Duke

Harpole, D. H., R. Petersen, S. Mukherjee, A. Bild, H. Dressman, R. Kratzke, M. J. Kelley, et al. “A genomic strategy to refine prognosis in early stage non-small cell lung carcinoma (NSCLC)..” In Journal of Clinical Oncology, 24:370S-370S. AMER SOC CLINICAL ONCOLOGY, 2006.

Scholars@Duke

Potti, A., H. K. Dressman, A. Bild, R. Riedel, M. Kelley, G. Ginsburg, J. Lancaster, J. Nevins, and P. Febbo. “A genomic strategy to combinatorial therapeutics in solid tumors..” J Clin Oncol 24, no. 18_suppl (June 20, 2006).

PMID
27952715
Scholars@Duke

Gajewski, TF, Niedzwiecki, D, Johnson, J, Linette, G, Bucher, C, Blaskovich, M, Sebti, S, and Haluska, F. "Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104." June 20, 2006.

Scholars@Duke

Vredenburgh, J. J., A. Desjardins, J. E. Herndon, J. Quinn, J. Rich, S. Sathornsumetee, H. S. Friedman, D. Reardon, S. Gururangan, and A. Friedman. “Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas..” In Journal of Clinical Oncology, 24:59S-59S. AMER SOC CLINICAL ONCOLOGY, 2006.

Scholars@Duke

Pages